Abstract Title:

Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients.

Abstract Source:

Eur J Clin Invest. 2020 Jan 21:e13201. Epub 2020 Jan 21. PMID: 31960952

Abstract Author(s):

L Bonfrate, D M Di Palo, G Celano, A Albert, P Vitellio, M De Angelis, M Gobbetti, P Portincasa

Article Affiliation:

L Bonfrate


BACKGROUND: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects.

MATERIALS AND METHODS: Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double-blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability, and intestinal microbiota were analysed at 0, 30, 45, and 60 days.

RESULTS: Percentage decrease from baseline of abdominal pain (-48.8% vs. -3.5%), bloating (-36.35% vs. +7.35%) and severity of disease (-30.1% vs. -0.4%) was significantly (p<0.0001) greater with LBB than placebo, respectively. In IBS-D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6±0.4 to 4.3±1.1, P<0.00001) than placebo (from 6.2±0.7 to 5.3±1.1, P=0.04). In IBS-C patients, Bristol score tended to improve from baseline after LBB (2.6±1.1 vs. 3.2 ± 0.5, P=0.06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 ± 0.1 vs. 1.1 ± 0.2, p=0.01). During treatment, presumptive lacticacid bacteria and Bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased.

CONCLUSIONS: The novel formulation of B. longum BB536 and L.rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability, and gut microbiota in IBS patients.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.